Covered recipient · General Payments record
FRANK B MARXER
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2024
$794.46
- Reported across 42 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $195.50 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $68.43 | 3 |
| Novo Nordisk AS | $32.48 | 2 |
| SANOFI-AVENTIS U.S. LLC | $24.65 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.47 | 1 |
| Acerta Pharma LLC | $18.10 | 1 |
| Lilly USA, LLC | $17.56 | 1 |
| ABBVIE INC. | $13.81 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.81 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104978111 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.10 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105618831 | CMS |
| GlaxoSmithKline, LLC. | $19.69 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116690107 | CMS |
| GlaxoSmithKline, LLC. | $19.03 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116365329 | CMS |
| GlaxoSmithKline, LLC. | $29.71 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116693849 | CMS |
| Lilly USA, LLC | $17.56 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134997432 | CMS |
| Novartis Pharmaceuticals Corporation | $20.47 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087029062 | CMS |
| Novo Nordisk Inc | $19.18 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096898814 | CMS |
| Novo Nordisk Inc | $13.30 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097487157 | CMS |
| SANOFI-AVENTIS U.S. LLC | $24.65 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139839515 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.